Acta Med. 2012, 55: 47-49

Surgical Management of Severe Spontaneous Hemorrhage of the Abdominal Wall Complicating Acenocoumarol Treatment

Orestis Ioannidisa, George Paraskevasb, Anastasios Kotronisa, Stavros Chatzopoulosa, Athina Konstantaraa, Nikolaos Papadimitrioua, Apostolos Makrantonakisa, Emmanouil Kakoutisa

aFirst Surgical Department, General Regional Hospital 'George Papanikolaou'. Thessaloniki, Greece
bDepartment of Anatomy, Medical School, Aristotle University of Thessaloniki, Greece

Received June 23, 2011
Accepted January 20, 2012


1. Casais P, Luceros AS, Meschengieser S, Bermejo E, Lazzari MA. INR variability in anticoagulation with acenocoumarol: is it useful for identifying patients at risk of bleeding and thrombosis? Haematologica 1999; 84: 753–4.
2. Casais P, Luceros AS, Meschengieser S, Fondevila C, Santarelli MT, Lazzari MA. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol 2000; 63: 192–6. <<192::AID-AJH5>3.0.CO;2-K>
3. Eckman MH, Levine HJ, Pauker SG. Effect of laboratory variation in the prothrombin‑time ratio on the results of oral anticoagulant therapy. N Engl J Med 1993; 329: 696–702. <>
4. Federle MP, Pan KT, Pealer KM. CT criteria for differentiating abdominal hemorrhage: anticoagulation or aortic aneurysm rupture? AJR Am J Roentgenol 2007; 188: 1324–30. <>
5. González‑García R, Schoendorff G, Muñoz‑Guerra MF, Rodríguez‑Campo FJ, Naval‑Gías L, Sastre‑Pérez J. Upper airway obstruction by sublingual hematoma: a complication of anticoagulation therapy with acenocoumarol. Am J Otolaryngol 2006; 27: 129–32. <>
6. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association. Circulation 1994; 89: 1469–80. <>
7. Ingerslev J, Vanek T, Culic S. Use of recombinant factor VIIa for emergency reversal of anticoagulation. J Postgrad Med 2007; 53: 17–22. <>
8. Koo S, Kucher N, Nguyen PL, Fanikos J, Marks PW, Goldhaber SZ. The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant‑related major hemorrhage. Arch Intern Med 2004; 164: 1557–60. <>
9. Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Büller HR, Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008; 111: 4471–6. <>
10. Pérez‑Andreu V, Roldán V, Antón AI, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 2009; 113: 4977–9. <>
11. Saraeva RB, Paskaleva ID, Doncheva E, Eap CB, Ganev VS. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. J Clin Pharm Ther 2007; 32: 641–9. <>
12. Topgül K, Uzun O, Anadol AZ, Gök A. Surgical management of enoxaparin‑ and/ or warfarin‑induced massive retroperitoneal bleeding: report of a case and review of the literature. South Med J 2005; 98: 104–6. <>
13. Vayá A, Martínez M, Fernández A, et al. The effect of acenocoumarol on hemorheological parameters. Clin Hemorheol Microcirc 2001; 24: 111–5.
14. Verde Z, Ruiz JR, Santiago C, Valle B, et al. A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One 2010; 5: e11210. <> <PubMed>
15. Wey PF, Petitjeans F, Lions C, Ould‑Ahmed M, Escarment J. Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion. Am J Geriatr Pharmacother 2008; 6: 173–7. <>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)